香港, 2025年8月14日 - (亞太商訊 via SeaPRwire.com) - 富衛集團有限公司（「富衛集團」或「富衛」）今天宣布了12項社區關愛撥款計劃，支援亞洲各地的本地社區，慶祝成立 12週年。自2013年成立以來，富衛集團從香港特別行政區、澳門特別行政區和泰國起步，現已擴展至亞洲共十個市場，包括柬埔寨、印尼、日本、馬來西亞、菲律賓、新加坡和越南。12項社區關愛撥款計劃將聚焦支持非政府機構，推動涵蓋理財素養、社會創業、就業準備及身心健康福祉等範疇的倡議。富衛集團行政總裁兼執行董事黃清風表示：「今年以新上市公司的身份慶祝富衛成立12週年，令這個里程碑更具意義。人壽保險業務極具個人化，而富衛現已服務亞洲三千萬客戶及其家庭。我們以『細心關懷』為核心價值之一，透過實質且有影響力的方式回饋社會，是實現我們為大眾創造保險新體驗此願景的重要實踐。」富衛集團於今年早前宣佈與JA（Junior Achievement）Worldwide延長合作夥伴關係。JA Worldwide是一家專注於青少年發展的慈善機構，也是 2025 年諾貝爾和平獎的提名機構。富衛與JA共同開發且屢獲殊榮的理財素養課程，預期到2027年底將惠及亞洲40,000多名學生。計劃的下一階段將透過推出全新教學工具，並與更多教師和家長攜手合作，加強於理財素養，心理健康和韌性的教育和知識。12項慈善機構撥款計劃包括：- 柬埔寨：與 Cambodia Children's Fund合作，推出「Let’s Save Debate」計劃，透過辯論與研究活動提升大學生的理財素養；- 香港：與青年成就香港部合作，進一步擴展「JA小財智．大夢想」課程，推出「JA SparktheDream同『理』．理財工作坊」，為小學生提供結合理財素養及社交情感學習的互動教育；支持睿動香港透過運動賦予青少年女性心理健康與自信；- 印尼：與 KUMPUL.ID 合作，支持「InnovateHer Academy 3.0」計劃，為女性企業家提供商業技能培訓、導師指導及投資準備課程；與Prestasi Junior Indonesia合作，並借鑒「JA小財智．大夢想」計劃的成功經驗，為30名學校教師提供技術培訓，讓他們能有效地為學生傳授理財素養課程；- 日本：與 NPO全國福祉理美容師養成協會（National Welfare Beauty and Barber Training Association）合作，在國際乳癌關注月向癌症患者提供醫療假髮及支援；- 馬來西亞：與GivingHub啟動「Bijak Ibu Jaga Anak & Kewangan （B.I.J.A.K. ）」計劃，為200個低收入家庭舉辦工作坊，推廣健康及理財素養，並提供200項健康篩查與諮詢服務；- 菲律賓：與Junior Achievement Philippines合作，通過「JA Forward Your Success」計劃協助應屆大學畢業生規劃財務與職業發展；- 新加坡：支持 Club Rainbow （Singapore）的「Ride and Walk for Rainbows 2025」活動，為長期病患兒童及其家人提供支援，並安排罕見遺傳及神經疾病青少年參觀萬態野生動物世界（Mandai Wildlife Reserve）；- 泰國：與Pimali Foundation合作資助七個酒店管理培訓獎學金，以協助弱勢青年建立可持續的職涯發展；與Junior Achievement Thailand合作，進一步擴展「JA小財智．大夢想」計劃，培訓30名教師，深化其理財素養技能以支援學生；- 越南：與 Startup Vietnam Foundation合作，支援「Be A Finnovator」計劃，舉辦大學生培訓及辯論比賽，培養金融知識、批判性思維與負責任的理財習慣。關於富衛集團富衛集團為泛亞洲人壽及健康保險公司，服務約三千萬名客戶，業務遍及亞洲十個市場，包括印尼人民銀行人壽保險（BRI Life）。富衛秉持以客為先的方針及科技賦能的模式，致力為客戶帶來創新定位、簡單易明的產品和簡單的保險體驗。自2013年成立以來，富衛於部分全球發展最迅速的保險市場營運業務，專注為大眾創造保險新體驗。富衛集團是香港聯合交易所有限公司主板上市的公司，股份代號為1828。如欲了解更多資訊，請瀏覽www.fwd.com Copyright 2025 亞太商訊 via SeaPRwire.com.

ACN Newswire

Kangji Medical Receives Privatisation Proposal from a Consortium Led by Kangji Medical’s Chairman, Zhong Ming, TPG and QIA to Advance Long-Term Strategic Vision

08/14/2025

Kangji Medical Holdings Limited and Knight Bidco Limited today jointly announced the pre-conditional proposal for the privatisation of Kangji Medical Holdings Limited by way of a scheme of arrangement (the “Proposal”).Proposed privatisation of Kangji Medical Holdings LimitedThe Cancellation Price of HK$9.25 per share represents a 21.7% premium over the closing price on 30 June, 2025, being the Undisturbed Date, a 47.3% premium over the 360-trading day average closing price up to and including the Undisturbed Date, and exceeds the highest closing price as quoted on the Stock Exchange since 2022The proposed privatisation will be effected by way of a scheme of arrangement; the Offeror Concert Parties collectively hold 74.75% shares in the Company; an Irrevocable Undertaking has been received from one institutional shareholder to vote in favour of the ProposalThe Proposal presents shareholders with certainty over their ability to monetise their interests in Kangji Medical Holdings Limited, following a period of sustained pressure on trading prices and limited liquidityHONG KONG, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - Aug 12 2025, Kangji Medical Holdings Limited (“Kangji Medical” or the “Company”, Stock Code: 9997.HK) and Knight Bidco Limited (the “Offeror”) today jointly announced a privatisation proposal. The parties intend to implement the privatisation of the Company by way of a scheme of arrangement, with a view to enabling the Company to focus on long-term strategic decisions, such as longer-term business investment in R&D and operations enhancements.Upon completion of the Proposal, the Company will become a wholly-owned subsidiary of the Offeror, and the listing of the Shares will be withdrawn from the Stock Exchange.The Offeror is owned by a consortium comprising Mr. Zhong and Ms. Shentu (the Founders), the TPG Entities, NewQuest V and Al-Rayyan Holding. Rationale for the ProposalDue to the long-term underperformance in the trading prices and trading liquidity of the Shares, the ability of the Company to raise funds from the equity market has been significantly limited. In addition, the Company has to incur administrative, compliance and other listing related costs and expenses for maintaining the listing status. Accordingly, there are limited benefits for the Company to maintain its listing status.In light of intensifying competition in domestic market and ongoing regulatory uncertainties, and in order to achieve sustainable growth, the Company's long-term strategy requires significant investment which could create short-term pressure on the Company’s financial performance. It is anticipated that additional resources need to be allocated to areas including sales and marketing, investment in research, development, and commercialisation, and the Company’s market expansion outside of China.Considering this, and the listing-related costs, there are limited benefits for Kangji Medical to maintain its listing status. In addition, the implementation of the Proposal will alleviate pressure on Kangji Medical’s short-term financial performance, which enables better focus on strategic objectives. It is anticipated that additional resources will need to be allocated for its future sustainable growth.Furthermore, the Proposal provides minority shareholders an attractive opportunity to realise compelling returns amid market volatility, industry and macro uncertainties, and the limited liquidity of the Shares.Knight Bidco Limited’s proposal offers a timely solution to Kangji Medical and its shareholders. Its proposal to privatise Kangji Medical will:(a) reduce Kangji Medical’s administrative, compliance and other listing related costs;(b) relieve Kangji Medical from the pressure associated with short-term performance metrics and enable Kangji Medical to focus on long-term strategic decisions (such as longer-term investment in R&D and operations enhancements which might incur short-term losses); and(c) present shareholders with certainty over their ability to monetise their interests in Kangji Medical at an attractive premium to the undisturbed share price.In summary, the Offeror believes that a take-private transaction is the strategic alternative that provides immediate and most compelling value for all shareholders, while also avoiding exposure to uncertain market conditions.Overview of the ProposalThe proposal sets out a Cancellation Price of HK$9.25 per share, valuing the company at approximately US$1.4 billion on an equity value basis.[1]The Offeror has indicated the Cancellation Price is final and will not be increased further.The Cancellation Price reflects:A 21.7% premium over the closing price on the Undisturbed Date (being 30 June, 2025).A 47.3% premium over the closing price of 360-trading day average price up to and including the Undisturbed Date.An 84.6% premium over the 52-week closing low (HK$5.01) up to and including the Undisturbed Date.A Cancellation Price above the highest closing price as quoted on the Stock Exchange since 2022 (HK$8.66).The Cancellation Price has taken into account, among other things, the recent and historical prices of the Shares traded on the Stock Exchange, publicly available financial information of the Company and with reference to other similar privatisation transactions in Hong Kong in recent years.The Proposal is subject to satisfaction of the Pre-Conditions by the Pre-Condition Long Stop Date (being 31 January, 2026) and the Conditions by the Long Stop Date (being 30 April, 2026). The Company will appoint an independent financial adviser (the “IFA”) to advise the committee of directors who are considered independent for the purposes of the Proposal (the “Independent Directors”) for the purposes of making a recommendation to shareholders in connection with the Proposal. Details of the Proposal including the Independent Directors’ final recommendation on the Proposal and the IFA’s advice will be included in the Scheme Document, expected to be dispatched to shareholders in due course.Scheme MeetingDetails of the Scheme Meeting to be convened will be contained in the Scheme Document which is expected to be dispatched to shareholders in due course.There are several pre-conditions and conditions as set out in the Joint Announcement, including regulatory approvals, shareholders approval and compliance with other legislative requirements.Irrevocable UndertakingAn Irrevocable Undertaking has been received from one institutional shareholder to vote in favour of the Proposal. Further details are available in the Joint Announcement.Trading in the Shares of the Company has been suspended on the Stock Exchange since 9:00 a.m. on 18 July, 2025, pending the release of this Announcement. The Company has applied to the Stock Exchange for the resumption of trading of Shares with effect from 9 a.m. on August 13, 2025.J.P. Morgan acted as the exclusive financial advisor to the Offeror.Kangji Medical Holdings LimitedKangji Medical is a medical device group founded in 2004 with headquarters at Hangzhou, Zhejiang Province, China. It was listed at the mainboard of the Stock Exchange of Hong Kong in June 2020 (Stock Code: 9997.HK). The Company specializes in the design, development, manufacture and sale of minimally invasive surgery instruments and accessories (“MISIA”). It strives for the mission of “providing physicians with high-quality products and services, and dedicating to improve people’s health”. The Company offers a comprehensive product portfolio to provide physicians and hospitals one-stop and tailored surgical solutions primarily for four major surgical specialties, including obstetrics and gynecology, general surgery, urology, and thoracic surgery. It is also committed to developing an internationally recognized minimally invasive surgery instruments and accessories platform with global coverage.About Knight Bidco LimitedEach of the Offeror, MidCo and TopCo is a newly incorporated company in the Cayman Islands with limited liability and an investment holding company set up solely for the purposes of implementing the Proposal. As at the date of the announcement, the Offeror is wholly owned by MidCo, which in turn is wholly owned by TopCo. As at the date of this announcement, TopCo is held by the Consortium Members, as to approximately 25.53% by Fortune Spring ZM, approximately 14.47% by Fortune Spring YG, approximately 24.38% by TPG Asia VII, approximately 5.01% by Keyhole, approximately 5.69% by Knight Success, approximately 4.56% by NewQuest V and approximately 20.36% by Al-Rayyan Holding. As at the date of this announcement, save as disclosed in the section headed “Shareholding Structure of the Company” in the Joint Announcement, none of TPG Asia VII, Keyhole, Knight Success, NewQuest V and Al-Rayyan Holding is a Shareholder.Kangji Medical is controlled by Mr. Zhong and his spouse Ms. Shentu who together hold 52.98% of the shares in Kangji Medical. Following the privatisation of Kangji Medical, Mr. Zhong and Ms. Shentu will remain the largest shareholders in the ultimate parent company of the Offeror, holding 40.00% of the shares in TopCo via Fortune Spring ZM and Fortune Spring YG. Further details are available in the Joint Announcement.Each of the Founder Entities is a business company incorporated in the British Virgin Islands.Knight Success is a newly incorporated company in Singapore with limited liability and an investment holding company. Keyhole is an exempted company incorporated in the Cayman Islands with limited liability and an investment holding company. TPG Asia VII is a company incorporated in Singapore with limited liability. Each of Knight Success and Keyhole is either wholly owned or controlled by TPG Asia VII, which is in turn controlled by TPG Asia GenPar VII Advisors, Inc. and ultimately controlled by TPG Inc., a publicly traded Delaware corporation (NASDAQ).TPG is a leading global alternative asset management firm founded in 1992 with more than US$269 billion of assets under management as of 30 June 2025. For many years, TPG has been investing in transformation, growth, and innovation and aims to build dynamic products and strategies for its investors while also instituting discipline and operational excellence across its investment strategies and performance of its portfolios.NewQuest V is a company incorporated in Singapore with limited liability and an investment holding company. NewQuest V is wholly owned by NewQuest Asia Fund V, L.P., which is in turn controlled by NewQuest Asia Fund V GP Ltd. and ultimately controlled by TPG Inc., a publicly traded Delaware corporation (NASDAQ).Established in 2011, NewQuest is one of Asia’s leading secondary private equity platforms with the most experienced secondary team in Asia across five offices. Since its founding, NewQuest has focused on working with GPs to create bespoke, tailored solutions to meet liquidity and other strategic needs of private asset owners and their stakeholders. Starting from a strategic partnership forged in 2018, NewQuest became wholly owned by TPG in January 2022.Al-Rayyan Holding is a limited liability company established in 2012 under the regulations of the Qatar Financial Centre Authority in the State of Qatar, and is a 100%-owned indirect subsidiary of QIA, the sovereign wealth fund of the State of Qatar. QIA was founded in 2005 to invest and manage the state reserve funds. QIA is among the largest and most active sovereign wealth funds globally. QIA invests across a wide range of asset classes and regions as well as in partnership with leading institutions around the world to build a global and diversified investment portfolio with a long-term outlook. As at the date of this announcement, Al-Rayyan Holding and its concert parties (other than those who are, or deemed to be, acting in concert with Al-Rayyan Holding solely in connection with the Consortium) are not interested in any Shares.For enquiries, please contact:Kangji Medical Holdings LimitedOfferorMedia contact: Wonderful Sky Financial Group LimitedAngie Li & Jason LaiTel: +852 6150 8598 / +852 9798 0715Email: po@wsfg.hkMedia contact: Brunswick GroupKatelin Stevenson & Tong Li+852 9875 3351 / +86 134 8872 6729TeamKnight@brunswickgroup.com[1] Based on HK$9.25 Cancellation Price per share, 1,207,994,000 shares outstanding, and USD/HKD of 7.85All capitalized terms which are used in this press release but not otherwise defined herein shall have the meanings ascribed to them in the Joint Announcement dated 12 August, 2025. This press release should be read in conjunction with the Joint Announcement, a copy of which is available on https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0812/2025081201338.pdf. Copyright 2025 ACN Newswire via SeaPRwire.com.

1 …77 78 79 80 81 … 177